IDENTIFICATION OF RESPONDER AND DISEASE ACTIVITY THRESHOLDS FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) QUESTIONNAIRE USING POOLED DATA FROM TWO PHASE 3 TRIALS OF BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS

被引：1
|
作者：
Gossec, L. [1 ,2 ]
Coates, L. [3 ]
Orbai, A. M. [4 ]
De Wit, M. [5 ]
Pelligra, C. [6 ]
Lambert, J. [7 ]
Ciaravino, V. [7 ]
Ink, B. [8 ]
Taieb, V. [7 ]
Gladman, D. D. [9 ]
机构：
[1] Sorbonne Univ, Paris, France
[2] Hop La Pitie Salpetriere, AP HP, Paris, France
[3] Univ Oxford, Nuffield Dept Orthopaed, Rheumatol & Musculoskeletal Sci, Oxford, England
[4] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD USA
[5] Stichting Tools, Amsterdam, Netherlands
[6] Evidera, Medellin, Colombia
[7] UCB Pharma, Colombes, France
[8] UCB Pharma, Slough, Berks, England
[9] Univ Toronto, Schroeder Arthrit Inst, Krembil Res Inst, Toronto Western Hosp, Toronto, ON, Canada
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Psoriatic arthritis; Clinical trials; Patient reported outcomes; OUTCOME MEASURE; VALIDATION;
D O I：
10.1136/annrheumdis-2023-eular.1980
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0590-HP
引用
收藏
页码：565 / 566
页数：2
相关论文
共 50 条
  • [31] Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry
    Umut Kalyoncu
    Sedat Kiraz
    Sule Apras Bilgen
    Omer Karadag
    Ali Akdogan
    Levent Kilic
    Abdulsamet Erden
    Berkan Armagan
    Alper Sari
    Ihsan Ertenli
    Clinical Rheumatology, 2019, 38 : 1187 - 1192
  • [32] Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry
    Kalyoncu, Umut
    Kiraz, Sedat
    Bilgen, Sule Apras
    Karadag, Omer
    Akdogan, Ali
    Kilic, Levent
    Erden, Abdulsamet
    Armagan, Berkan
    Sari, Alper
    Ertenli, Ihsan
    CLINICAL RHEUMATOLOGY, 2019, 38 (04) : 1187 - 1192
  • [33] The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting
    Di Carlo, Marco
    Becciolini, Andrea
    Lato, Valentina
    Crotti, Chiara
    Favalli, Ennio Giulio
    Salaffi, Fausto
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (03) : 279 - 285
  • [34] Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
    Philip J. Mease
    Ana-Maria Orbai
    Oliver FitzGerald
    Mohamed Bedaiwi
    Rajiv Dona L. Fleishaker
    Pamela Mundayat
    Philip S. Young
    Arthritis Research & Therapy, 25
  • [35] Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
    Mease, Philip J.
    Orbai, Ana-Maria
    FitzGerald, Oliver
    Bedaiwi, Mohamed
    Fleishaker, Dona L.
    Mundayat, Rajiv
    Young, Pamela S.
    Helliwell, Philip
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [36] FURTHER ANALYSIS OF PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE (PASDAS) AND COMPOSITE PSORIATIC DISEASE ACTIVITY INDEX (CPDAI) USING DATA FROM A PLACEBO-CONTROLLED TRIAL OF CERTOLIZUMAB PEGOL IN PSORIATIC ARTHRITIS
    Helliwell, P.
    Mease, P. J.
    Nurminen, T.
    FitzGerald, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 740 - 740
  • [37] BIMEKIZUMAB IMPACT ON CORE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS DOMAINS FOR PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM FOUR PHASE 3 STUDIES
    Merola, Joseph F.
    Mease, Philip J.
    Deodhar, Atul
    Ink, Barbara
    Fleurinck, Carmen
    Bajracharya, Rajan
    Coarse, Jason
    Coates, Laura C.
    RHEUMATOLOGY, 2024, 63
  • [38] Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies
    Merola, Joseph F.
    Mease, Philip J.
    Deodhar, Atul
    Ink, Barbara
    Fleurinck, Carmen
    Bajracharya, Rajan
    Coarse, Jason
    Coates, Laura C.
    RHEUMATOLOGY, 2024, 63
  • [39] Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year
    Ritchlin, Christopher
    Rahman, Proton
    Helliwell, Philip
    Boehncke, Wolf-Henning
    McInnes, Iain
    Gottlieb, Alice
    Kafka, Shelly
    Kollmeier, Alexa
    Hsia, Elizabeth
    Xu, Xie
    Shawi, May
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Ramachandran, Paraneedharan
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [40] POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR
    Ritchlin, C. T.
    Rahman, P.
    Helliwell, P.
    Boehncke, W. H.
    Mcinnes, I.
    Gottlieb, A. B.
    Kafka, S.
    Kollmeier, A.
    Hsia, E. C.
    Xu, X. L.
    Shawi, M.
    Sheng, S.
    Agarwal, P.
    Zhou, B.
    Ramachandran, P.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1300 - 1301
12345